



Fig. S3 Methylation status of the MIR888 promoter. Analysis of the promoter region ranging 2000 bps upstream of the transcription start site in tumor types with reported overexpression of miR-888-5p (** $p < 0.01$). UCEC: Uterine Corpus Endometrial Carcinoma, PRAD: Prostate adenocarcinoma, BRCA: Breast Invasive Carcinoma, and LIHC: Liver Hepatocellular Carcinoma. COAD: colon adenocarcinoma. (** $p < 0.01$)